Healthcare / Drug Manufacturers - Specialty & GenericBSE
$3.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $2.9M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$169M
P/E
39.4x
↑EV/EBITDA
43.8x
↑ROE
0.9%
↑Gross Margin
51.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.3%
FCF CAGR
-35.6%
FCF margin
2.5%
FCF / Net income
4.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $113.3M · net income $670000.0 · FCF $2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $113.3M | $113.3M | $144.7M | $131.4M | $223.7M |
| Net Income | $670000.00 | $670000.00 | $2.0M | $778000.00 | $3.1M |
| EBITDA | $3.8M | $3.8M | $7.9M | $4.0M | $9.6M |
| EPS | 0.01 | 0.01 | 0.04 | 0.01 | 0.06 |
| Gross Margin | 51.4% | 51.4% | 41.7% | 36.0% | 40.8% |
| Operating Margin | 1.3% | 1.3% | 4.0% | -1.8% | 0.6% |
| Net Margin | 0.6% | 0.6% | 1.4% | 0.6% | 1.4% |
| Cash Flow | |||||
| Free Cash Flow | $2.9M | $2.9M | $16.3M | $-9.5M | $10.8M |
| Returns | |||||
| ROE | 0.9% | 0.9% | 2.8% | 1.1% | 4.3% |
| Valuation | |||||
| P/E | 39.38 | 39.38 | — | — | — |
| EV/EBITDA | 43.77 | 43.77 | — | — | — |
| P/B | 2.29 | 2.29 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -21.7% | -21.7% | 10.2% | -41.3% | — |
| EPS Growth | -67.1% | -67.1% | 170.5% | -75.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
3Y implied EPS CAGR
182.0%
EPS terminal req.
$0.28
Spread vs growth
-249.0%
5Y implied EPS CAGR
93.5%
EPS terminal req.
$0.34
Spread vs growth
-160.6%
10Y implied EPS CAGR
45.9%
EPS terminal req.
$0.54
Spread vs growth
-113.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.3%
Start / end P/E
119.4x → 252.6x
EPS bridge
0.04 → 0.01
Residual
-74.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.